Jonathan Deshazo, PhD, MPH

CVS Health, United States

Disclosure information not submitted.

Presentation(s):

• Evaluation of Febrile Seizure Risk Following Ancestral Monovalent COVID-19 mRNA Vaccination Among U.S. Children Aged 2-5 Years

  Monday, August 26, 2024
  2:15 PM – 2:30 PM CEST

• Considerations for Negative Control Outcome Analyses in Vaccine Effectiveness Studies: Post-Hoc Analyses from an Adult Vaccine Effectiveness Study conducted within the FDA BEST Initiative

  Tuesday, August 27, 2024
  8:30 AM – 8:45 AM CEST

• Effectiveness Over Time of a Complete Primary Series of the Original, Monovalent COVID-19 Vaccines Among Adults Aged 18-64 Years in the United States

  Tuesday, August 27, 2024
  9:15 AM – 9:30 AM CEST

• Polypharmacy among Adolescents and Young Adults Newly Initiating Anti-Anxiety and Anti-Depressive Medications

  Wednesday, August 28, 2024
  9:15 AM – 9:30 AM CEST